We retrospectively analyzed the factors that affect serum cyclosporine (CsA) concentrations up to day 14 after allogeneic hematopoietic stem cell transplantation (HSCT). In all, 103 transplant recipients who received MTX and CsA for acute GVHD prophylaxis were analyzed. No significant relationships between serum CsA concentrations and gender, age, serum creatinine levels, AST/ALT levels, or antibiotic/fluconazole administration were found by comparing median CsA concentrations or by using longitudinal or regression multivariate analyses. However, the mean of the median serum CsA concentration in patients (n ¼ 54) receiving the regimen containing cyclophosphamide (CY) (149.7 ng/ml; 95% confidence interval (CI): 132.1-167.4) was significantly (Po0.0001) lower than that in patients (n ¼ 49) receiving the non-CY regimen (217.3 ng/ml; 95% CI: 198.9-235.6). Longitudinal analysis and regression multivariate analysis showed that only administration of CY had a significant effect on the serum CsA concentration. Our results suggest that administration of CY during conditioning can reduce the effects on serum CsA concentrations during the 2 weeks following HSCT. The mechanism of this effect is not clear, but it may be due to the autoinduction of CY.
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The prevention of acute GVHD is one of the critical challenges in allogeneic hematopoietic stem cell transplantation (HSCT). [1] [2] [3] The most commonly used regimen for the prevention of acute GVHD is the combination of a short course of MTX and cyclosporine (CsA).
1,2 The administration of CsA can be difficult, because it has a narrow therapeutic range and because its serum level can be affected pharmacologically by many substances, such as fluconazole, macrolide antibiotics, and calcium channel blockers. [4] [5] [6] An increased serum CsA concentration may induce nephrotoxicity and neurotoxicity; decreased concentrations may cause severe acute GVHD. [1] [2] [3] [5] [6] [7] [8] CsA is metabolized primarily by cytochrome P-450 enzymes, which exist in the endoplasmic reticulum, especially high concentrations in hepatocytes and the enterocytes of the intestine. 4 In P-450 enzymes, P-450 3A4 predominantly metabolizes CsA, and this enzyme family is subjected to both induction and inhibition by several agents. 9, 10 Induction occurs when a drug induces or accelerates another drug's metabolism by P-450 enzymes. Inhibition occurs when two different drugs require metabolism by the same P-450 enzyme and compete for binding and metabolism by that enzyme. 4 Cyclophosphamide (CY) is widely used for the conditioning regimen of HSCT with other agents. CY is a prodrug requiring bioactivation before exerting cytotoxicity. 11 The first reaction involves a 4-hydroxylation to produce 4-hydroxycyclophosphamide (4-HC). 11 This step is mediated by the cytochrome P-450 enzymes 2A6, 2B6, 2C9, 2C18, 2C19, 3A4, and 3A5. [12] [13] [14] [15] 4-HC is detoxified by aldehyde dehydrogenase to yield the inactive carboxyphosphamide or is oxidized to form 4-ketocyclophosphamide. [16] [17] [18] Deschloroethylcyclophosphamide and chloroacetaldehyde are formed through the inactivation of CY by side chain oxidation mediated by CYP3A4. 15, 19, 20 Continuous infusion and repeated administration results in an increased total clearance with no alteration in the volume of distribution or renal clearance, and hence a decreased elimination half-life due to low liver extraction. [21] [22] [23] Through this course, CYP2C9, CYP2B6, and CYP3A4 are induced in human hepatocytes; this mechanism is called autoinduction. 24, 25 Autoinduction results in the increased clearance of the drug during treatment with an increased formation of 4-HC, phosphoramide mustard, and 2-dechloroethylcyclophosphamide. 22, 23, [26] [27] [28] [29] [30] In general, autoinduction is detectable within 24 h of administration. Cheng et al 31, 32 reported that the hepatic transformation of CY to its active metabolite 4-HC may be increased in patients with breast cancer by the coadministration of drugs that induce human P-450. The rapid development of enhanced clearance after high doses of CY causes an increase in the clearance of dexamethasone, which is eliminated by CYP3A4, through an induction of hepatic metabolic enzymes. 22, 33 We retrospectively analyzed the factors that may affect the serum CsA concentration during a short period, up to day 14, after HSCT.
Materials and methods

Patients
We analyzed patients who received allogeneic HSCT at our hospital from April 1995 to March 2001. The inclusion criteria for this study were: (1) with hematologic malignancies; (2) allogeneic HSCT; (3) two or more measurements of CsA concentrations from days 3 to 14 after HSCT; (4) a short course of MTX and CsA for prophylaxis of acute GVHD; (5) age X18 years old; (6) conditioning regimen containing TBI; (7) no previous HSCT; and (8) no prior history of CsA administration.
Administration of CsA
CsA was administered at 3 mg/kg intravenously for 10 h from day À1 of transplantation and was administered orally after patients could take sufficient nutrition orally. Until day 14 after HSCT, all patients received CsA intravenously. Blood specimens were collected to assess the trough levels. The CsA levels were measured with a monoclonal antibody using FPIA. 34, 35 Treatment at HSCT MTX was administered at 15 mg/m 2 on day 1 and at 10 mg/ m 2 on days 3, 6, and 11. Four conditioning regimens were performed according to the patients' diseases and the donor types: (1) TBI (12 Gy) þ CY (60 mg/kg once daily d.i.v. for 2 days) for ALL/lymphoma patients with an unrelated donor; (2) TBI (12 Gy) þ granulocytecolony-stimulating factor (G-CSF: 5 mg/kg continuous i.v. for 4 consecutive days) combined with high-dose Ara-C (G/Ara: cytarabine 3 g/m 2 twice daily d.i.v. for 4 consecutive days) for AML/ CML/MDS patients with a related donor; (3) TBI (12 Gy) þ G-CSF (5 mg/kg continuous d.i.v. for 2 consecutive days) combined with high-dose Ara-C (cytarabine 3 g/ m 2 twice daily d.i.v. for 2 consecutive days) þ CY (60 mg/kg once daily d.i.v. for 2 days) for AML/CML/MDS patients with an unrelated donor; and (4) TBI (12 Gy) þ etoposide (60 mg/kg, continuous i.v. for 24 h) for ALL/lymphoma patients with a related donor. All patients received the same prophylaxes of acyclovir for HSV infection and immunoglobulin for CMV. G-CSF was administered at 5 mg/kg by continuous i.v. from day 5 for patients treated with BMT or PBSCT and from day 1 for patients treated with cord blood transplantation.
Analysis
Median serum CsA concentrations between days 3 and 14 after HSCT were compared. Day 3 was selected based on the half-life of CsA and its steady state. Day 14 was selected to minimize the effects of increased doses of CsA in response to severe acute GVHD, decreased doses of CsA due to CsA toxicities, or the administration of additional immunosuppressants. Comparisons of the means of median CsA levels were performed with the t-test using JMP software (SAS Institute). The longitudinal analysis was performed using the SAS system (SAS Institute). In this analysis, a linear mixed effects model was applied in order to account for the correlation among observations within each subject and missing data. Intravariability and intervariability (correlation among observations per subject) were taken into account in the analysis by introducing the concept of random effects. Missing data were considered to be missing at random or missing completely at random. 36 This approach has the advantages of (i) the avoidance of multiple comparisons between the two treatments over time points and (ii) the estimation of the time trend of treatment efficacy over a study period. Regression multivariate analyses were performed by two random effects models to account for the intervariability and to derive robust results. First, a linear mixed effects model with the intercept as a random effect was applied, and second, the model with both the intercept and slope as random effects was applied. Possible covariates, that is, patients' backgrounds, disease, risk, donor type, HLA match, hepatic function and serum creatinine level, and interventions, that is, the administration of CY, the administration of fluconazole, and the duration of fluconazole (none, o10 days, or X10 days), were selected by a step-down procedure. This approach was based on a robust estimation of variance in which the highest parameter among those with P-values of the Wald's statistic X0.05 was subsequently excluded. The term 'significant' was used when the P-value was below 0.05.
Results
Characteristics of patients
The number of eligible patients was 103 out of 179 cases. Of these, 76 cases were excluded, for the following reasons: under 18 years old (24 patients), no short course of MTX and CsA prophylaxis (24 patients), insufficient number of measurements of CsA levels or insufficient data (10 patients), second HSCT (seven patients), nonmalignant hematological diseases (five patients), conditioning regimen without TBI (three patients), and mortal condition or death before day 14 (three patients). Patient characteristics are summarized in Table 1 . The median number of measurements of the serum CsA levels from days 3 to 14 was four (range: 2-9). CsA doses were decreased and/or the administration of CsA was omitted in 10 patients due to increased levels of CsA and/or the occurrence of CsArelated toxicities. CsA doses were increased in four patients because of low serum CsA levels. Data obtained before dose adjustments were used for these patients.
Age and gender Figure 1 shows the relationship between age and median concentration of CsA. No significant relationship was Effect of CY at conditioning on serum CsA levels observed between these two factors (r 2 ¼ 0.0474). The means of the median concentrations of CsA in male and female patients were 180.1 and 183.5 ng/ml, respectively (P ¼ 0.8168).
Renal function and hepatic function
At day 0 of HSCT, two patients showed serum creatinine levels higher than the institutional normal range (o1.0 mg/ dl). The means of the serum CsA levels in these two patients and in normal patients were 182.9 and 144.8 ng/dl, respectively. At day 0 of HSCT, 92 patients showed normal hepatic function (both AST and ALT within the institutional normal range). The means of the median serum CsA levels of the normal hepatic function group and abnormal group were 178.8 and 209.8 ng/ml, respectively (P ¼ 0.1845).
Antifungal and antibiotic agents
In total, 69 patients were treated with fluconazole; three patients were treated with amphotericin B; and one patient was treated with itraconazole. The mean of the median serum CsA concentrations in those patients who were not treated with fluconazole (n ¼ 34) was 185.8 ng/ml with a 95% confidence interval (CI) of 160.8-210.7. The mean of the median serum CsA concentrations in those receiving fluconazole for 1-9 days (n ¼ 19) was 172.0 ng/ml (95% CI: 137.7-206.3), and that in patients receiving fluconazole for longer than 9 days (n ¼ 50) was 183.4 ng/ml (95% CI: 162.8-204.4). A total of 87 patients received antibacterial agents, primarily b-lactam antibacterials, and no patients were treated with macrolide antibacterials. The means of the median concentrations of serum CsA in the nonantibiotic group and antibiotic group were 200.8 ng/ml (95% CI: 164.8-236.9) and 178.7 ng/ml (95% CI: 163. 2-194.3) . No significant differences were observed when the means of the median serum CsA levels were compared between the nonantibiotic patients and patients treated with any of the 27 antibiotics administered (data not shown). Figure 2 shows the distributions of the median serum CsA concentrations among each of the conditioning regimen. The means of the median serum CsA concentrations were as follows: for TBI þ CY (n ¼ 14), 157.0 ng/ml (95% CI: 123.0-191.0); for TBI þ G/Ara þ CY (n ¼ 33), 200.5 ng/ml (95% CI: 182.9-227.2); for TBI þ G/Ara (n ¼ 40), 147.1 ng/ ml (95% CI: 126.7-167.5); and for TBI þ etoposide (n ¼ 16), 242.6 ng/ml (95% CI: 201.8-274.4). Significant differences were observed between the CY-containing regimens and the non-CY regimens: Figure 1 Relationship between age and median serum CsA concentrations. Scattering plots of the relationship between age and median serum CsA levels. The X-axis shows the age of patients, and the Y-axis shows the median serum CsA level of each patient. The correlation between age and the mean serum CsA levels was not significant (r 2 ¼ 0.0474).
Conditioning regimen
Effect of CY at conditioning on serum CsA levels F Nagamura et al (P ¼ 0.0031); and TBI þ G/Ara þ CY vs TBI þ etoposide (Po0.0001). Figure 3 shows the distributions of the median serum CsA concentrations in the CY-containing regimen group (TBI þ CY regimen and TBI þ G/Ara þ CY regimen) and the non-CY regimen group (TBI þ G/Ara regimen and TBI þ etoposide regimen). The means of the median serum CsA concentrations of the CY-containing regimen group (n ¼ 54) and non-CY regimen group (n ¼ 49) were 149.7 ng/ ml (95% CI: 132.1-167.4) and 217.3 ng/ml (95% CI: 198.9-235.6), respectively (Po0.0001). Table 2 shows the demographic data of the CYcontaining and the non-CY regimen groups. Patient age, donor type (related or unrelated), and the administration of antibiotics were significantly imbalanced between these two groups. To clarify the impacts of these imbalances, we performed a subgroup analysis. As shown in Table 3 and Figure 4a and b, no significant differences were observed between a younger group and an elderly group, between a related donor group and an unrelated donor group, or between a no antibiotic group and an antibiotic group in the both regimen groups. Effect of CY at conditioning on serum CsA levels
Longitudinal analysis
According to longitudinal analysis, only the presence or absence of CY in the conditioning regimen (ie, CY-containing regimen vs non-CY regimen) had a significant influence on the serum CsA levels. The other factors had insignificant impacts. Figure 5 shows the longitudinal changes in the means and standard deviations of the serum CsA levels in the CY-containing regimen group and the non-CY regimen group. From day 0, that is, 24 h after the first CsA administration, a significant difference in the increment of serum CsA levels was observed between the two groups. The serum CsA levels increased with significant differences in the increments until day 14. Days after HSCT CY (−) CY (+) Figure 5 Longitudinal analysis of the serum CsA levels in the CYcontaining regimen group and the non-CY regimen group. CY(À) shows the longitudinal changes of the means of serum CsA in the non-CY regimen group (interrupted line) and CY ( þ ) shows those of the CY-containing regimen group (solid line). Vertical lines at each day show the standard deviation of the serum CsA levels. The difference in the increment of serum CsA levels in the two groups at day 0 was significant, and the serum CsA levels of the two groups increased and maintained significant differences of the increment. The number of patients at day 8 in the non-CY regimen group was two, and that at day 9 in the non-CY regimen was one. At the other points, serum CsA levels were measured in more than three patients.
Effect of CY at conditioning on serum CsA levels F Nagamura et al
Regression multivariate analysis Table 4 shows the results of the regression multivariate analysis of models 1 and 2. In model 1, CY (Po0.001), time (Po0.001), CY Â time (P ¼ 0.914), disease (P ¼ 0.106), and renal function (P ¼ 0.070) remained at step 8. In model 2, CY (Po0.001), time (P ¼ 0.069), and time Â CY (P ¼ 0.900) remained at step 9. In both models 1 and 2, CY showed a significant relationship with serum CsA concentrations.
Acute GVHD
The median day of the onset of acute GVHD in all patients was day 19. 
Discussion
The diversity of drug interactions with CsA is closely related to its metabolic pathway. CsA is metabolized mainly by the hepatic P-450 enzyme CYP3A4 and partially by CYP3A5. 9, 37 Metabolites of CsA are excreted into the bile. 10 Less than 1% of CsA is excreted in an unchanged form in urine. Another metabolic pathway involves P-glycoprotein, which is a membrane efflux pump that keeps intracellular drug concentrations low by transporting the drug out of the cell. Since P-glycoprotein is located on the epithelium of intestinal cells, it can act as a counter transport pump that transports drugs back into the intestinal lumen and thus plays an important role in the absorption of orally administered CsA. 37 Although the metabolic pathway via P-glycoprotein is important, this mechanism has no impact on this study because all of the patients received CsA intravenously. Drugs that have interactions with CsA are generally metabolized by hepatic P-450, and this overlapping metabolic pathway is considered the main mechanism of drug effects on CsA levels. 5, 6, 38 Physical attributes, such as gender and age, have also been reported related to the serum CsA concentrations. 39, 40 As younger people have a more rapid CL and a larger Vss than the elderly, caution with serum CsA doses based on differences in age has been claimed to be required. 39 Our results showed that the serum CsA concentration was not influenced by age, gender, administration of fluconazole, or administration of antibacterials.
Several studies have indicated that transplantations from unrelated donors are associated with higher risks of both acute GVHD and regimen-related toxicity. [41] [42] [43] As McDonald et al 44 reported, CY causes liver injury when its use is followed by TBI. It affects liver metabolism and the mortality of patients. These situations can result in an increased proportion of inflammatory cytokines. 45, 46 The recognition of foreign host antigens by donor T cells and the stimulation, and proliferation of T cells during the early period after an unrelated donor transplantation results in elevated levels of many inflammatory cytokines, such as IL-1, IL-2, TNF-a, and IFN-g. [46] [47] [48] Regimen-related toxicity also induces inflammatory cytokines, such as IL-1, GM-CSF, TNF-a, and IFN-g, because activated cells from the damaged recipient tissues secrete these cytokines. 48 These inflammatory cytokines have been reported to suppress cytochrome P-450 enzyme activities. [48] [49] [50] Given these facts, the disproportionate number of patients who received unrelated donor transplantations in the CYcontaining regimen group has to be considered. Neither the time until the onset of acute GVHD nor the severity of acute GVHD showed significant differences between the CY-containing regimen group and the non-CY regimen group. Furthermore, patients who exhibited a mortal condition (including VOD) and died before day 14 were excluded from this study. Two patients received HSC from unrelated donors and one from a related donor. Additionally, the difference in donors (related or unrelated) was not a significant factor according to longitudinal and multivariate regression analyses. Based on these facts, inflammatory cytokines related to the difference in donor type did not play a critical role in determining the serum CsA levels.
In this study, three methods were used: comparisons of the median serum CsA levels, the longitudinal method, and multivariate regression analysis. Only the administration of CY during conditioning for HSCT was a significant factor according to all three methods. One hypothesis that can explain this observation is the autoinduction of CY. The high doses of CY during conditioning could induce autoinduction, and activated hepatic enzymes may reduce the serum CsA levels. Hepatic enzymes, CYP2C9, CYP2B6, and CY3A4, are activated by the autoinduction of CY. 24, 25 CY3A4 is the primary hepatic enzyme that metabolizes CsA, and it may contribute to a reduction in Effect of CY at conditioning on serum CsA levels serum CsA levels. 9, 10 Longitudinal analysis showed that a significant difference of increment in serum CsA levels was observed at day 0 of HSCT. As autoinduction of CY generally begins within 24 h of CY administration, this rapid progression could explain the occurrence of this early significant difference. Another hypothesis is that administration of CY may activate the renal elimination of CsA. However, no reports have been published to support this hypothesis.
Serum CsA concentrations were significantly lower in the CY-containing regimen group than in the non-CY regimen group. However, the difference in the incidence of grade X2 acute GVHD was not significant. Many factors, for example, donor type (related or unrelated), HLA match, stem cell source (BM, PBSC, or CB), and additional therapies influence the severity of acute GVHD. It is difficult to conclude that the low serum CsA concentrations that were induced by the administration of CY had the impact on the occurrence of severe acute GVHD and/or chronic GVHD. A prospective study with well-balanced patient demographic data may answer this concern.
Our data revealed one factor that influences CsA pharmacokinetics: the administration of CY. To clarify the mechanism of this action, further studies based on the expression of CY P-450 and other genes related to CsA pharmacokinetics are required.
